Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

James Q. Nguyen,Geraldine Helen OSullivan Coyne,Naoko Takebe,Abdul Rafeh Naqash,Jessica Mukherjee,Ashley Bruns,Richard Piekarz,Jerry M. Collins,Larry D. Anderson,Brandon Miller,Ralph E. Parchment,Larry Rubinstein,Shivaani Kummar,Elad Sharon,Howard Streicher,Alice P. Chen,James H. Doroshow

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

2021

James Q. Nguyen
Geraldine Helen OSullivan Coyne
Naoko Takebe
Abdul Rafeh Naqash
Jessica Mukherjee
Ashley Bruns
Richard Piekarz
Jerry M. Collins
Larry D. Anderson
Brandon Miller
Ralph E. Parchment
Larry Rubinstein
Shivaani Kummar
Elad Sharon
Howard Streicher
Alice P. Chen
James H. Doroshow

3088Background: The nucleoside analog Aza-TdC inhibits DNA methyltransferase 1 (DNMT1), which regulates methylation-mediated silencing of tumor suppressor genes. Aza-TdC offers an improvement over ...

Keywords:

Nucleoside
DNA methyltransferase
Medicine
in patient
Gene silencing
Suppressor
4-Thio-2-deoxycytidine
DNMT1
Cancer research
Gene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations